NICE Technology Appraisal 176 |
Cetuximab for the first-line treatment of metastatic colorectal cancerSummary:
|
Web address: www.nice.org.uk/Guidance/TA176 |
NICE Technology Appraisal 177 |
Alitretinoin for the treatment of severe chronic hand eczemaSummary:
|
Web address: www.nice.org.uk/Guidance/TA177 |
NICE Technology Appraisal 178 |
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinomaSummary:
|
Web address: www.nice.org.uk/Guidance/TA178 |
No comments yet